Pharmacological and genetic modifications of somatic cholesterol do not substantially alter the course of CNS disease in Niemann-Pick C mice

J Inherit Metab Dis. 2000 Feb;23(1):54-62. doi: 10.1023/a:1005650930330.

Abstract

Niemann-Pick type C (NPC) is a neurodegenerative disorder with somatically altered cholesterol metabolism. The NPC1 gene has recently been cloned and shown to have sequences shared with known sterol-sensing proteins. We have used a mouse model with a disrupted Npc1 gene to study two cholesterol-lowering drugs (nifedipine and probucol) and the effects of introducing a null mutation in the low-density lipoprotein receptor (LDLR). Although these treatments significantly ameliorated liver cholesterol storage, little effect on the onset of neurological symptoms was found.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood-Brain Barrier
  • Cholesterol / metabolism*
  • Mice
  • Mice, Inbred BALB C
  • Mice, Knockout
  • Niemann-Pick Diseases / drug therapy*
  • Niemann-Pick Diseases / genetics
  • Nifedipine / therapeutic use*
  • Probucol / therapeutic use*
  • Receptors, LDL / physiology*

Substances

  • Receptors, LDL
  • Cholesterol
  • Nifedipine
  • Probucol